36 research outputs found
Clinical, hormonal and ovarian morphological correlation in women with polycystic ovary syndrome
Background: Aim of the study was to study the correlation between clinical, ultrasonographical and hormonal features in women diagnosed as polycystic ovary syndrome (PCOS) and association with vitamin D levels.Methods: This prospective study was conducted among women attending gynecological outpatient department (OPD) of Subharti Medical College, Meerut over a period of two years among 100 patients with clinical diagnosis of PCOS/PCOD according to Rotterdam criteria (2013) were included in this study. All biochemical investigations to be carried out for levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), vitamin D levels, lipid profile to understand the endocrinal and metabolic derangements if any in the patient. Ultrasound pelvis for ovarian study was conducted to know the ovarian morphology, no of follicles if any and their size, which were helpful in the diagnosis of PCOS.Results: Nulliparity and multiparity was reported among 32% and 68% of the subjects respectively. Most common complaint was hirsuitism (43%). According to ultrasonography (USG), PCOS was found to be positive and negative among 87% and 13% of the subjects respectively. Most of the subjects had vitamin D level of 20-50 while <20 vitamin D level was found among 27% of the subjects. Vitamin D deficiency was found to be more in subjects having morphological presence of PCOS as compared to subjects with morphological absence of PCOS with statistically significant difference.Conclusions: On correlating ultrasonological findings with clinic hormonal changes in PCOS women we found that hirsuitism and vitamin d deficiency was significantly more common in women with sonological findings suggestive of PCOS
Increased localization of APP-C99 in mitochondria-associated ER membranes causes mitochondrial dysfunction in Alzheimer disease
In the amyloidogenic pathway associated with Alzheimer disease (AD), the
amyloid precursor protein (APP) is cleaved by beta-secretase to generate
a 99-aa C-terminal fragment (C99) that is then cleaved by c-secretase to
generate the beta-amyloid (Ab) found in senile plaques. In previous
reports, we and others have shown that c-secretase activity is enriched
in mitochondria-associated endoplasmic reticulum (ER) membranes (MAM)
and that ER-mitochondrial connectivity and MAM function are upregulated
in AD. We now show that C99, in addition to its localization in
endosomes, can also be found in MAM, where it is normally processed
rapidly by c-secretase. In cell models of AD, however, the concentration
of unprocessed C99 increases in MAM regions, resulting in elevated
sphingolipid turnover and an altered lipid composition of both MAM and
mitochondrial membranes. In turn, this change in mitochondrial membrane
composition interferes with the proper assembly and activity of
mitochondrial respiratory supercomplexes, thereby likely contributing to
the bioenergetic defects characteristic of AD.We thank Drs. Orian Shirihai and Marc Liesa (UCLA) for assistance with
the Seahorse measurements, Dr. Huaxi Xu (Sanford Burnham Institute) for
the APP-DKO MEFs and Dr. Mark Mattson (NIH) for the PS1 knock-in mice,
Drs. Arancio and Teich for the APP-KO mice tissues used in these
studies, Dr. Hua Yang (Columbia University) for mouse husbandry, and
Drs. Marc Tambini, Ira Tabas, and Serge Przedborski for helpful
comments. This work was supported by the Fundacion Alfonso Martin
Escudero (to M.P.); the Alzheimer's Drug Discovery Foundation, the
Ellison Medical Foundation, the Muscular Dystrophy Association, the U.S.
Department of Defense W911NF-12-1-9159 and W911F-15-1-0169), and the J.
Willard and Alice S. Marriott Foundation (to E.A.S.); the U.S. National
Institutes of Health (P01-HD080642 and P01-HD032062 to E.A.S.; NS071571
and HD071593 to M.F.M.; R01-NS056049 and P50-AG008702 to G.D.P.;
1S10OD016214-01A1 to G.S.P. and F.P.M, and K01-AG045335 to E.A.-G.), the
Lucien Cote Early Investigator Award in Clinical Genetics from the
Parkinson's Disease Foundation (PDF-CEI-1364 and PDF-CEI-1240) to
C.G.-L., and National Defense Science and Engineering Graduate
Fellowship (FA9550-11-C-0028) to R.R.A.S
Recommended from our members
Alzheimer’s-associated upregulation of mitochondria-associated ER membranes after traumatic brain injury
23 p.-5 fig.-3 tab.-1 graph. abst.Traumatic brain injury (TBI) can lead to neurodegenerative diseases such as Alzheimer’s disease (AD) through mechanisms that remain incompletely characterized. Similar to AD, TBI models present with cellular metabolic alterations and modulated cleavage of amyloid precursor protein (APP). Specifically, AD and TBI tissues display increases in amyloid-β as well as its precursor, the APP C-terminal fragment of 99 a.a. (C99). Our recent data in cell models of AD indicate that C99, due to its affinity for cholesterol, induces the formation of transient lipid raft domains in the ER known as mitochondria-associated endoplasmic reticulum (ER) membranes (“MAM” domains). The formation of these domains recruits and activates specific lipid metabolic enzymes that regulate cellular cholesterol trafficking and sphingolipid turnover. Increased C99 levels in AD cell models promote MAM formation and significantly modulate cellular lipid homeostasis. Here, these phenotypes were recapitulated in the controlled cortical impact (CCI) model of TBI in adult mice. Specifically, the injured cortex and hippocampus displayed significant increases in C99 and MAM activity, as measured by phospholipid synthesis, sphingomyelinase activity and cholesterol turnover. In addition, our cell type-specific lipidomics analyses revealed significant changes in microglial lipid composition that are consistent with the observed alterations in MAM-resident enzymes. Altogether, we propose that alterations in the regulation of MAM and relevant lipid metabolic pathways could contribute to the epidemiological connection between TBI and AD.Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This work was supported by the U.S. National Institutes of Health (T32-DK007647 to RRA; R21NS125395 to LS; S10-OD016214 and P30-CA013330 to FPM; R01-EB029523 to WM; R01-NS095803 to SGK; R01-NS088197 to RJD; R01-AG056387 to EA-G) and the U.S. Department of Defense (National Defense Science and Engineering Graduate Fellowship, FA9550-11-C-0028, to RRA).Peer reviewe
Recommended from our members
Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
BACKGROUND Regular, detailed reporting on population health by underlying cause of death is fundamental for public health decision making. Cause-specific estimates of mortality and the subsequent effects on life expectancy worldwide are valuable metrics to gauge progress in reducing mortality rates. These estimates are particularly important following large-scale mortality spikes, such as the COVID-19 pandemic. When systematically analysed, mortality rates and life expectancy allow comparisons of the consequences of causes of death globally and over time, providing a nuanced understanding of the effect of these causes on global populations. METHODS The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 cause-of-death analysis estimated mortality and years of life lost (YLLs) from 288 causes of death by age-sex-location-year in 204 countries and territories and 811 subnational locations for each year from 1990 until 2021. The analysis used 56 604 data sources, including data from vital registration and verbal autopsy as well as surveys, censuses, surveillance systems, and cancer registries, among others. As with previous GBD rounds, cause-specific death rates for most causes were estimated using the Cause of Death Ensemble model-a modelling tool developed for GBD to assess the out-of-sample predictive validity of different statistical models and covariate permutations and combine those results to produce cause-specific mortality estimates-with alternative strategies adapted to model causes with insufficient data, substantial changes in reporting over the study period, or unusual epidemiology. YLLs were computed as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 1000-draw distribution for each metric. We decomposed life expectancy by cause of death, location, and year to show cause-specific effects on life expectancy from 1990 to 2021. We also used the coefficient of variation and the fraction of population affected by 90% of deaths to highlight concentrations of mortality. Findings are reported in counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2021 include the expansion of under-5-years age group to include four new age groups, enhanced methods to account for stochastic variation of sparse data, and the inclusion of COVID-19 and other pandemic-related mortality-which includes excess mortality associated with the pandemic, excluding COVID-19, lower respiratory infections, measles, malaria, and pertussis. For this analysis, 199 new country-years of vital registration cause-of-death data, 5 country-years of surveillance data, 21 country-years of verbal autopsy data, and 94 country-years of other data types were added to those used in previous GBD rounds. FINDINGS The leading causes of age-standardised deaths globally were the same in 2019 as they were in 1990; in descending order, these were, ischaemic heart disease, stroke, chronic obstructive pulmonary disease, and lower respiratory infections. In 2021, however, COVID-19 replaced stroke as the second-leading age-standardised cause of death, with 94·0 deaths (95% UI 89·2-100·0) per 100 000 population. The COVID-19 pandemic shifted the rankings of the leading five causes, lowering stroke to the third-leading and chronic obstructive pulmonary disease to the fourth-leading position. In 2021, the highest age-standardised death rates from COVID-19 occurred in sub-Saharan Africa (271·0 deaths [250·1-290·7] per 100 000 population) and Latin America and the Caribbean (195·4 deaths [182·1-211·4] per 100 000 population). The lowest age-standardised death rates from COVID-19 were in the high-income super-region (48·1 deaths [47·4-48·8] per 100 000 population) and southeast Asia, east Asia, and Oceania (23·2 deaths [16·3-37·2] per 100 000 population). Globally, life expectancy steadily improved between 1990 and 2019 for 18 of the 22 investigated causes. Decomposition of global and regional life expectancy showed the positive effect that reductions in deaths from enteric infections, lower respiratory infections, stroke, and neonatal deaths, among others have contributed to improved survival over the study period. However, a net reduction of 1·6 years occurred in global life expectancy between 2019 and 2021, primarily due to increased death rates from COVID-19 and other pandemic-related mortality. Life expectancy was highly variable between super-regions over the study period, with southeast Asia, east Asia, and Oceania gaining 8·3 years (6·7-9·9) overall, while having the smallest reduction in life expectancy due to COVID-19 (0·4 years). The largest reduction in life expectancy due to COVID-19 occurred in Latin America and the Caribbean (3·6 years). Additionally, 53 of the 288 causes of death were highly concentrated in locations with less than 50% of the global population as of 2021, and these causes of death became progressively more concentrated since 1990, when only 44 causes showed this pattern. The concentration phenomenon is discussed heuristically with respect to enteric and lower respiratory infections, malaria, HIV/AIDS, neonatal disorders, tuberculosis, and measles. INTERPRETATION Long-standing gains in life expectancy and reductions in many of the leading causes of death have been disrupted by the COVID-19 pandemic, the adverse effects of which were spread unevenly among populations. Despite the pandemic, there has been continued progress in combatting several notable causes of death, leading to improved global life expectancy over the study period. Each of the seven GBD super-regions showed an overall improvement from 1990 and 2021, obscuring the negative effect in the years of the pandemic. Additionally, our findings regarding regional variation in causes of death driving increases in life expectancy hold clear policy utility. Analyses of shifting mortality trends reveal that several causes, once widespread globally, are now increasingly concentrated geographically. These changes in mortality concentration, alongside further investigation of changing risks, interventions, and relevant policy, present an important opportunity to deepen our understanding of mortality-reduction strategies. Examining patterns in mortality concentration might reveal areas where successful public health interventions have been implemented. Translating these successes to locations where certain causes of death remain entrenched can inform policies that work to improve life expectancy for people everywhere. FUNDING Bill & Melinda Gates Foundation
Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries
Abstract
Background
Healthcare cannot achieve net-zero carbon without addressing operating theatres. The aim of this study was to prioritize feasible interventions to reduce the environmental impact of operating theatres.
Methods
This study adopted a four-phase Delphi consensus co-prioritization methodology. In phase 1, a systematic review of published interventions and global consultation of perioperative healthcare professionals were used to longlist interventions. In phase 2, iterative thematic analysis consolidated comparable interventions into a shortlist. In phase 3, the shortlist was co-prioritized based on patient and clinician views on acceptability, feasibility, and safety. In phase 4, ranked lists of interventions were presented by their relevance to high-income countries and low–middle-income countries.
Results
In phase 1, 43 interventions were identified, which had low uptake in practice according to 3042 professionals globally. In phase 2, a shortlist of 15 intervention domains was generated. In phase 3, interventions were deemed acceptable for more than 90 per cent of patients except for reducing general anaesthesia (84 per cent) and re-sterilization of ‘single-use’ consumables (86 per cent). In phase 4, the top three shortlisted interventions for high-income countries were: introducing recycling; reducing use of anaesthetic gases; and appropriate clinical waste processing. In phase 4, the top three shortlisted interventions for low–middle-income countries were: introducing reusable surgical devices; reducing use of consumables; and reducing the use of general anaesthesia.
Conclusion
This is a step toward environmentally sustainable operating environments with actionable interventions applicable to both high– and low–middle–income countries
Landing CG on EARTH: A Case Study of Fine-Grained Multithreading on an Evolutionary Path
We report on our work in developing a fine-grained multithreaded solution for the communicationintensive Conjugate Gradient (CG) problem. In our recent work, we developed a simple yet efficient program for sparse matrix-vector multiply on a multithreaded system. This paper presents an effective mechanism for the reduction-broadcast phase, which is integrated with the sparse MVM, resulting in a scalable implementation of the complete CG application. Three major observations from our experiments on the EARTH multithreaded testbed are: (1) The scalability of our CG implementation is impressive, e.g., absolute speedup is 90 on 120 processors for the NAS CG class B input. (2) Our dataflow-style reductionbroadcast network based on fine-grain multithreading is twice as fast as a serial reduction scheme on the same system. (3) By slowing down the network by a factor of 2, no notable degradation of overall CG performance was observed. 1. Introduction Many existing or proposed parallel machin..